Literature DB >> 20074418

Timing of relapse in short-course chemotherapy trials for tuberculosis.

A J Nunn1, P P J Phillips, D A Mitchison.   

Abstract

We have reviewed the results from 15 tuberculosis treatment trials initiated by the British Medical Research Council between 1970 and 1983 in Africa and East Asia. Of 574 relapses, 447 (78%) occurred within 6 months of stopping treatment and 525 (91%) within 12 months. We suggest that investigators should consider terminating follow-up after the last enrolled patient completes 6 months following treatment, while continuing to follow patients enrolled earlier until that time. Compared to following all patients to 24 months, the total trial duration could be reduced by 18 months, with no increase in patient numbers in a non-inferiority design.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20074418

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  37 in total

1.  High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Authors:  Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Stefan V Goldberg; Lorna Bozeman; William J Burman; Kwok-Chiu Chang; Michael Chen; Mark Cotton; Kelly E Dooley; Melissa Engle; Pei-Jean Feng; Courtney V Fletcher; Phan Ha; Charles M Heilig; John L Johnson; Erica Lessem; Beverly Metchock; Jose M Miro; Nguyen Viet Nhung; April C Pettit; Patrick P J Phillips; Anthony T Podany; Anne E Purfield; Kathleen Robergeau; Wadzanai Samaneka; Nigel A Scott; Erin Sizemore; Andrew Vernon; Marc Weiner; Susan Swindells; Richard E Chaisson
Journal:  Contemp Clin Trials       Date:  2020-01-22       Impact factor: 2.226

2.  False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes.

Authors:  Grant Theron; Rouxjeane Venter; Liezel Smith; Aliasgar Esmail; Philippa Randall; Vishesh Sood; Suzette Oelfese; Greg Calligaro; Robin Warren; Keertan Dheda
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

3.  Linezolid for XDR-TB--Final Study Outcomes.

Authors:  Myungsun Lee; Sang Nae Cho; Clifton E Barry; Taeksun Song; Youngran Kim; Ina Jeong
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

4.  Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.

Authors:  Francesca Conradie; Andreas H Diacon; Nosipho Ngubane; Pauline Howell; Daniel Everitt; Angela M Crook; Carl M Mendel; Erica Egizi; Joanna Moreira; Juliano Timm; Timothy D McHugh; Genevieve H Wills; Anna Bateson; Robert Hunt; Christo Van Niekerk; Mengchun Li; Morounfolu Olugbosi; Melvin Spigelman
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

5.  CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

Authors:  Payam Nahid; Jussi Saukkonen; William R Mac Kenzie; John L Johnson; Patrick P J Phillips; Janet Andersen; Erin Bliven-Sizemore; John T Belisle; W Henry Boom; Annie Luetkemeyer; Thomas B Campbell; Kathleen D Eisenach; Richard Hafner; Jeffrey L Lennox; Mamodikoe Makhene; Susan Swindells; M Elsa Villarino; Marc Weiner; Constance Benson; William Burman
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

6.  Time until relapse in tuberculosis treatment trials: implication for phase 3 trial design.

Authors:  John L Johnson; Bonnie A Thiel
Journal:  Am J Respir Crit Care Med       Date:  2012-09-01       Impact factor: 21.405

Review 7.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

8.  Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.

Authors:  Florian M Marx; Ted Cohen; Nicolas A Menzies; Joshua A Salomon; Grant Theron; Reza Yaesoubi
Journal:  Lancet Glob Health       Date:  2020-09       Impact factor: 26.763

9.  Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting.

Authors:  A C Pettit; L A Kaltenbach; F Maruri; J Cummins; T R Smith; J V Warkentin; M R Griffin; T R Sterling
Journal:  Int J Tuberc Lung Dis       Date:  2011-07       Impact factor: 2.373

Review 10.  Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis.

Authors:  Nicholas D Walter; Michael Strong; Robert Belknap; Diane J Ordway; Charles L Daley; Edward D Chan
Journal:  Respirology       Date:  2012-07       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.